Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer

Fineline Cube Dec 21, 2025
Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Fineline Cube Dec 20, 2025
Company Drug

MicuRx Pharmaceuticals Concludes US Phase I Study for MRX-8

Fineline Cube Oct 24, 2022

Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the conclusion of Phase I...

Company Drug

Henlius Biotech’s Hanbeitai Approved for Hepatocellular Carcinoma

Fineline Cube Oct 24, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving a fourth indication approval from the...

Company Drug

Antengene’s Xpovio Receives Taiwan FDA Approval for Multiple Indications

Fineline Cube Oct 24, 2022

China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving market approval from the Taiwan...

Company Drug

AIM Vaccine Receives CDE Approval for Serum-Free Rabies Vaccine Trial

Fineline Cube Oct 24, 2022

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving clinical trial approval from the...

Company Deals

Rici Healthcare to Acquire Unicorn II Holdings for RMB 180M

Fineline Cube Oct 24, 2022

China-based Rici Healthcare Holdings Limited (HKG: 1526), also known as Rich Healthcare, is set to...

Company

Roche Reports Q3 Sales Growth, Hit by COVID-19 Product Decline

Fineline Cube Oct 24, 2022

Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2022 financial report last week, showing...

Company

Ambrx Biopharma Halts Development of HER2 ADC ARX788, Cuts Workforce

Fineline Cube Oct 21, 2022

US-based, China-owned biotech Ambrx Biopharma Inc. (NYSE: AMAM) has announced plans to end the development...

Drug R&D

Sinopharm’s Wuhan Institute Isolates Monkeypox Strains, Begins Vaccine Research

Fineline Cube Oct 21, 2022

China’s Wuhan Institute of Biological Products, a research affiliate of Sinopharm’s China National Biotech Group...

Company Deals

CATUG Biotechnology Partners with Duoning to Advance mRNA Industrialization

Fineline Cube Oct 21, 2022

China-based CATUG Biotechnology (Suzhou) Co., Ltd has entered into a partnership with compatriot firm Shanghai...

Policy / Regulatory

Fujian Procurement Center Announces VBP for Cardiac and Laparoscopic Medical Consumables

Fineline Cube Oct 21, 2022

The Fujian drug and device joint procurement center has released two separate notifications regarding the...

Policy / Regulatory

NMPA Releases 61st Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Oct 21, 2022

The National Medical Products Administration (NMPA) has released the 61st batch of reference drugs for...

Company Drug

Betta Pharmaceuticals’ BPI-460372 Accepted for Clinical Trial Review by NMPA

Fineline Cube Oct 21, 2022

China’s Betta Pharmaceuticals (SHE: 300558) has announced that its clinical trial filing for the Category...

Company Drug

Frontier Biotechnologies Secures Approval for HIV Therapy Alfusid

Fineline Cube Oct 21, 2022

Nanjing-based Frontier Biotechnologies Inc. has announced that its supplementary market filing for Alfusid (albuvirtide), China’s...

Company Drug

Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China

Fineline Cube Oct 21, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd’s...

Company Drug

China Approves GSK’s Juluca for HIV-1 Infection

Fineline Cube Oct 21, 2022

The National Medical Products Administration (NMPA) has approved the market application for GlaxoSmithKline’s (GSK, NYSE:...

Company Drug

Hengrui Medicine Files for Dalpiciclib as Initial Therapy for Breast Cancer

Fineline Cube Oct 21, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced a supplementary market filing for...

Company Deals

HitGen Partners with C4X Discovery to Identify Novel Inflammatory Disease Treatments

Fineline Cube Oct 20, 2022

China-based HitGen Inc. (SHA: 688222) has announced a partnership with UK-headquartered C4X Discovery Holdings plc...

Company

Abbott Reports Q3 Sales Growth, Raises Full-Year EPS Guidance

Fineline Cube Oct 20, 2022

With the Q3 2022 reporting season underway, US-based medtech giant Abbott (NYSE: ABT) released its...

Company Policy / Regulatory

Shaanxi Releases Notice for Inter-Provincial Orthodontic Brackets VBP

Fineline Cube Oct 20, 2022

The Shaanxi Public Resources Trading Center has released the “Inter-provincial Alliance (regions, Corps) Orthodontic Brackets...

Company Drug

Hainan Poly Pharm’s Generic Ganciclovir Approved in Sweden for CMV Retinitis

Fineline Cube Oct 20, 2022

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving technical review approval from...

Posts pagination

1 … 546 547 548 … 600

Recent updates

  • Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration
  • BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer
  • BeOne Medicines Names Dual Presidents in Leadership Overhaul
  • Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline
  • TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Company Drug

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer

Company

BeOne Medicines Names Dual Presidents in Leadership Overhaul

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.